Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.57 |
| ▸ | EDNRB | P24530 | 4/20 | 0.49 |
| ▸ | EDNRA | P25101 | 2/20 | 0.49 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.47 |
| ▸ | ICMT | O60725 | 2/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.46 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6091159 | 0.93 | PPARG (0.65) | PPARGEDNRBEDNRAF2RL3ICMT | |
| SCHEMBL6093344 | 0.91 | PPARG (0.65) | PPARGEDNRBEDNRAF2RL3ICMT | |
| SCHEMBL6093520 | 0.91 | PPARG (0.58) | PPARGEDNRBEDNRAF2RL3ICMT | |
| SCHEMBL6092255 | 0.91 | ICMT (0.48) | PPARGICMTSERPINE1GRIN1GRIN2B | |
| SCHEMBL6090091 | 0.87 | PPARG (0.57) | PPARGEDNRBEDNRAF2RL3ICMT | |
| SCHEMBL6093343 | 0.86 | PPARG (0.55) | PPARGEDNRBEDNRAF2RL3ICMT | |
| SCHEMBL6092537 | 0.86 | PPARG (0.59) | PPARGEDNRBEDNRAF2RL3SERPINE1 | |
| SCHEMBL5745661 | 0.85 | PPARG (0.54) | PPARGEDNRBEDNRAF2RL3ICMT | |
| SCHEMBL6858382 | 0.85 | PPARG (0.76) | PPARGEDNRBEDNRAF2RL3SERPINE1 | |
| SCHEMBL6091680 | 0.84 | PPARG (0.61) | PPARGEDNRBEDNRAF2RL3ICMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160879-A1 | Indoles useful in the treatment of inflammation | BIOLIPOX AB (SE) | 2006-07-20 | — | — | US | disclosed |
| EP-1646624-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005005415-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160879-A1 | Indoles useful in the treatment of inflammation | IDO1, PTGS1, IDO2 | PPARG 481/4885EDNRB 226/4885EDNRA 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.